Sun Pharmaceutical Industries, Inc.
🇺🇸United States
Clinical Trials
4
Active:3
Completed:1
Trial Phases
2 Phases
Phase 1:3
Phase 3:1
Drug Approvals
240
FDA:238
CANADA:1
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 24
- Next
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 3
1 (25.0%)European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Sun Pharmaceutical Industries, Inc.
- Target Recruit Count
- 407
- Registration Number
- NCT05041803
- Locations
- 🇫🇷
Service de Dermatologie CHRU de Brest - Hopital Morvan, Brest Cedex, Finistere, France
🇫🇷Service de Dermatologie Centre Hospitalier Universitaire de Nice - Hopital Archet 2, Nice, Provence-Alpes-Cote d'Azur, France
🇫🇷CHU de Bordeaux, Hopital Saint-Andre, Bordeaux, France
News
Sun Pharma Discontinues Psoriasis and Eczema Drug SCD-044 After Phase 2 Trial Failures
Sun Pharma's experimental oral drug SCD-044 (Vibozilimod) failed to meet primary endpoints in Phase 2 trials for both psoriasis and atopic dermatitis, missing the 75% improvement target in PASI and EASI scores at 16 weeks.